Dashboard
Manage Tickers

ANNXAnnexon, Inc.

Nasdaq annexonbio.com


$ 6.22 $ 0.47 (8.17 %)    

Monday, 09-Sep-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 2.72 (0.6 %)
DIA $ 409.08 $ 1.75 (0.43 %)
SPY $ 546.60 $ 1.93 (0.35 %)
TLT $ 99.96 $ 0.58 (0.58 %)
GLD $ 231.58 $ 0.32 (0.14 %)
$ 6.22
$ 5.78
$ 6.22 x 400
$ 6.23 x 200
$ 5.78 - $ 6.35
$ 1.57 - $ 8.40
612,633
na
844.89M
$ 1.18
$ 44.29
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-06-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 09-08-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-annexon
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:53:09

Cantor Fitzgerald analyst Josh Schimmer reiterates Annexon (NASDAQ:ANNX) with a Overweight.

annexon-presents-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with-anx007-in-ga-at-the-retina-society-57th-annual-meeting-and-24th-euretina-congress
Annexon Presents Phase 2 ARCHER Data On Pr...
09/09/2024 12:03:22

Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservat...

hc-wainwright--co-reiterates-buy-on-annexon-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on Anne...
08/13/2024 10:54:48

HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.

needham-reiterates-buy-on-annexon-maintains-16-price-target
Needham Reiterates Buy on Annexon, Maintai...
08/13/2024 09:54:08

Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.

annexon-q2-eps-023-inline
Annexon Q2 EPS $(0.23), Inline
08/12/2024 12:09:25

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 51.06 ...

annexon-presents-update-on-archer-ii-global-registrational-program-in-geographic-atrophy-topline-data-expected-in-second-half-2026
Annexon Presents Update On ARCHER II Globa...
08/05/2024 12:08:25

Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Addition...

bank-of-new-york-mellon-posts-upbeat-earnings-joins-archer-aviation-rivian-automotive-and-other-big-stocks-moving-higher-on-friday
Bank of New York Mellon Posts Upbeat Earni...
07/12/2024 14:27:17

reported-late-thursday-annexon-to-present-additional-phase-2-data-on-anx007s-visual-preservation-in-geographic-atrophy-at-42nd-asrs-meeting
Reported Late Thursday, Annexon To Present...
07/12/2024 07:46:05

Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
07/10/2024 17:35:24

annexon-shares-are-trading-higher-after-the-company-announced-that-it-presented-results-from-the-phase-3-trial-of-c1q-targeted-immunotherapy-anx005-in-guillain-barr-syndrome-at-the-2024-peripheral-nerve-society-annual-meeting
Annexon shares are trading higher after th...
06/26/2024 11:47:25

annexon-presents-results-from-completed-pivotal-phase-3-trial-of-c1q-targeted-immunotherapy-anx005-in-guillain-barr-syndrome
Annexon Presents Results From Completed Pi...
06/25/2024 21:02:19

Key Findings from the Phase 3 GBS Trial of ANX005 30 mg/kg Treatment Phase 3 trial informed by dose-ranging Phase 1b trial, ...

annexon-to-present-significant-phase-3-results-of-anx005-in-guillain-barr-syndrome-at-pns-annual-meeting-potential-to-be-first-targeted-therapy-for-gbs
Annexon to Present Significant Phase 3 Res...
06/18/2024 12:16:01

reported-earlier-annexon-prices-125m-underwritten-public-offering-of-13001120-common-shares-at-625share
Reported Earlier, Annexon Prices $125M Und...
06/06/2024 06:12:34

The pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the...

cantor-fitzgerald-reiterates-overweight-on-annexon
Cantor Fitzgerald Reiterates Overweight on...
06/05/2024 13:55:14

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Annexon (NASDAQ:ANNX) with a Overweight.

douyu-international-posts-q1-results-joins-annexon-dollar-tree-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
DouYu International Posts Q1 Results, Join...
06/05/2024 12:07:39

annexon-shares-are-trading-lower-after-the-company-announced-the-commencement-of-a-125-million-public-offering
Annexon shares are trading lower after the...
06/05/2024 12:07:23

why-stitch-fix-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket
Why Stitch Fix Shares Are Trading Higher B...
06/05/2024 09:27:25

annexon-commences-public-offering-of-125m-of-shares-of-its-common-stock
Annexon Commences Public Offering Of $125M...
06/04/2024 21:09:36

All of the shares are being offered by Annexon. In addition, Annexon expects to grant the underwriters a 30-day option to purch...

needham-reiterates-buy-on-annexon-maintains-16-price-target
Needham Reiterates Buy on Annexon, Maintai...
06/04/2024 19:16:54

Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.

hc-wainwright--co-reiterates-buy-on-annexon-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on Anne...
06/04/2024 18:57:42

HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION